See the DrugPatentWatch profile for vyvanse
What is Hikma's generic Vyvanse?
Hikma Pharmaceuticals is offering a generic version of lisdexamfetamine dimesylate capsules [1]. This medication is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged 6 years and older [1]. It is also used to treat moderate to severe binge eating disorder in adults [1].
When did generic Vyvanse become available?
Hikma announced the launch of its generic lisdexamfetamine dimesylate capsules in the United States on February 20, 2024 [1]. This launch followed the expiry of patent protections for the brand-name drug Vyvanse [2].
How does generic lisdexamfetamine work?
Lisdexamfetamine dimesylate is a prodrug of dextroamphetamine [1]. After oral administration, it is converted to dextroamphetamine, which is a central nervous system stimulant [1]. The exact mechanism of action for treating ADHD and binge eating disorder is not fully understood, but it is believed to involve modulating the activity of neurotransmitters like dopamine and norepinephrine in the brain [1].
What is the difference between Vyvanse and its generic version?
The generic version of lisdexamfetamine dimesylate capsules is expected to be therapeutically equivalent to brand-name Vyvanse [3]. The primary difference will be in the manufacturer and cost, with generic versions typically being more affordable [3].
Are there other generic options for Vyvanse?
Other manufacturers have also launched or are expected to launch generic versions of lisdexamfetamine dimesylate [2]. The availability of multiple generic options can increase competition and potentially drive down prices further [2]. DrugPatentWatch.com tracks the patent and exclusivity landscape for drugs like Vyvanse [4].
What are the potential side effects of generic lisdexamfetamine?
As with the brand-name drug, generic lisdexamfetamine dimesylate may cause side effects. These can include dry mouth, decreased appetite, insomnia, weight loss, and anxiety [1]. More serious side effects may involve cardiovascular issues, psychiatric problems, and the potential for abuse or dependence [1]. Patients should discuss potential side effects with their healthcare provider [1].
What is the regulatory status of generic Vyvanse?
Generic lisdexamfetamine dimesylate capsules have received approval from the U.S. Food and Drug Administration (FDA) [1]. This approval indicates that the generic product meets the same standards for quality, safety, and efficacy as the brand-name drug [3].
Who manufactures generic Vyvanse?
Hikma Pharmaceuticals is one of the manufacturers of generic lisdexamfetamine dimesylate capsules [1]. Other companies are also producing generic versions of the medication [2].
Sources:
1. Hikma Pharmaceuticals PLC. Hikma Announces Launch of Generic Vyvanse® (Lisdexamfetamine Dimesylate) Capsules in the U.S.
2. DrugPatentWatch. Lisdexamfetamine Dimesylate Patent Expiry
3. U.S. Food & Drug Administration. Generic Drugs: Questions & Answers
4. DrugPatentWatch.com